This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 13 print issues and online access
$259.00 per year
only $19.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Witkin JM, Golani LK, Smith JL. Clinical pharmacological innovation in the treatment of depression. Expert Rev Clin Pharmacol. 2023;16:349–62. https://doi.org/10.1080/17512433.2023.2198703.
Alt A, Nisenbaum ES, Bleakman D, Witkin JM. A role for AMPA receptors in mood disorders. Biochem Pharmacol. 2006;71:1273–88. https://doi.org/10.1016/j.bcp.2005.12.022.
Dijkstra F, O’Donnell P, Klaassen E, Buhl D, Asgharnejad M, Rosen L, et al. Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers. Transl Psychiatry. 2022;12:408. https://doi.org/10.1038/s41398-022-02148-w.
Kato AS, Burris KD, Gardinier KM, Gernert DL, Porter WJ, Reel J, et al. Forebrain-selective AMPA-receptor antagonism guided by TARP γ-8 as an antiepileptic mechanism. Nat Med. 2016;22:1496–501. https://doi.org/10.1038/nm.4221.
Radin DP, Li YX, Rogers G, Purcell R, Lippa A. Tarps differentially affect the pharmacology of ampakines. Biochem Pharmacol. 2018;154:446–51. https://doi.org/10.1016/j.bcp.2018.06.013.
Zhang D, Lape R, Shaikh SA, Kohegyi BK, Watson JF, Cais O, et al. Modulatory mechanisms of TARP γ8-selective AMPA receptor therapeutics. Nat Commun. 2023;14:1659. https://doi.org/10.1038/s41467-023-37259-5.
Author information
Authors and Affiliations
Contributions
JMW conceptualized the paper and both AL and JMW wrote and edited the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests. Both JMW and AL are employees of RespireRx Pharmaceuticals Inc. None of the compounds from this company are in clinical development for major depressive disorder.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Witkin, J.M., Lippa, A. Potentiation of AMPA receptors for rapid therapeutic gain in psychiatry has reached a new level of excitement. Neuropsychopharmacol. 49, 339–340 (2024). https://doi.org/10.1038/s41386-023-01651-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41386-023-01651-y
This article is cited by
-
Targeting metaplasticity mechanisms to promote sustained antidepressant actions
Molecular Psychiatry (2024)